TY - JOUR T1 - Antiretroviral therapy needs: the effect of changing global guidelines JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - ii62 LP - ii66 DO - 10.1136/sti.2010.046177 VL - 86 IS - Suppl 2 AU - Karen Stanecki AU - Juliana Daher AU - John Stover AU - Michel Beusenberg AU - Yves Souteyrand AU - Jesus M Garcia Calleja Y1 - 2010/12/01 UR - http://sti.bmj.com/content/86/Suppl_2/ii62.abstract N2 - Background In 2010 the WHO issued a revision of the guidelines on antiretroviral therapy (ART) for HIV infection in adults and adolescents. The recommendations included earlier diagnosis and treatment of HIV in the interest of a longer and healthier life. The current analysis explores the impact on the estimates of treatment needs of the new criteria for initiating ART compared with the previous guidelines.Methods The analyses are based on the national models of HIV estimates for the years 1990–2009. These models produce time series estimates of ART treatment need and HIV-related mortality. The ART need estimates based on ART eligibility criteria promoted by the 2010 WHO guidelines were compared with the need estimates based on the 2006 WHO guidelines.Results With the 2010 eligibility criteria, the proportion of people living with HIV currently in need of ART is estimated to increase from 34% to 49%. Globally, the need increases from 11.4 million (10.2–12.5 million) to 16.2 million (14.8–17.1 million). Regional differences include 7.4 million (6.4–8.4 million) to 10.6 million (9.7–11.5 million) in sub-Saharan Africa, 1.6 million (1.3–1.7 million) to 2.4 million (2.1–2.5 million) in Asia and 710 000 (610 000–780 000) to 950 000 (810 000–1.0 million) in Latin America and the Caribbean.Conclusions When adopting the new recommendations, countries have to adapt their planning process in order to accelerate access to life saving drugs to those in need. These recommendations have a significant impact on resource needs. In addition to improving and prolonging the lives of the infected individuals, it will have the expected benefit of reducing HIV transmission and the future HIV/AIDS burden. ER -